Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial

Ann Rheum Dis. 2013 Jan;72(1):146-8. doi: 10.1136/annrheumdis-2012-202071. Epub 2012 Jul 31.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • B-Cell Activating Factor / blood*
  • Double-Blind Method
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Rituximab
  • Sjogren's Syndrome / blood*
  • Sjogren's Syndrome / drug therapy*
  • Tumor Necrosis Factor Ligand Superfamily Member 13 / blood*

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • B-Cell Activating Factor
  • TNFSF13B protein, human
  • Tumor Necrosis Factor Ligand Superfamily Member 13
  • Rituximab